{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:08Z","timestamp":1792691768469,"version":"4.5.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized Homologous recombination deficient (HRD) solid tumors by using the synthetic lethality which BRCA 1\/2 mutated cancer cells depend on for DNA repair. Standard PARP inhibitors such as olaparib, rucaparib, niraparib, and talazoparib have been shown to inhibit both PARP1 and PARP2, and have shown significant clinical efficacy in breast, ovarian, prostate, and pancreatic cancers. However, their clinical efficacy is limited by their hematological toxicities such as anemia, thrombocytopenia, and neutropenia that requires reduction in dose and treatment discontinuation which compromises their therapeutic efficacy and long-term use. This review focuses on molecular mechanism, preclinical and clinical evidence highlighting the shift from standard dual PARP 1\/2 inhibitors into selective PARP1 inhibitors. Molecular and preclinical evidence has shown that inhibition of PARP1 is sufficient to induce synthetic lethality in HRD tumors, while inhibition of PARP2 causes hematopoietic stem and progenitor cell (HSPC) toxicity via impairment of erythropoiesis. These limitations led to the use of next-generation selective PARP1 inhibitors, such as saruparib (AZD5305), with approximately 500-fold higher selectivity for PARP1 over PARP2 with potent antitumor activity and reduced hematological toxicity. The clinical efficacy and tolerability of selective PARP1 inhibitors provides a significant opportunity to use them as combination therapy which was previously limited due to combined myelosuppression. Collectively PARP1 inhibitors have demonstrated clinically impactful advancement that exhibits anticancer effect without causing significant hematological toxicity. They have potential of treating patients who benefit from PARP1 inhibitor-based precision oncology.<\/jats:p>","DOI":"10.3389\/fonc.2026.1894818","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:38Z","timestamp":1784867018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Maha M.","family":"Ayoub","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayma A.","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Alkarbi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafia","family":"Anjum","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Malki","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-024-02069-w","article-title":"Cancer, metastasis, and the epigenome","volume":"23","author":"Kiri","year":"2024","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.213728","article-title":"The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection","volume":"286","author":"Coleman","year":"2011","journal-title":"J Biol Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.103","article-title":"Targeting DNA repair pathway in cancer: Mechanisms and clinical application","volume":"2","author":"Wang","year":"2021","journal-title":"MedComm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature05978","article-title":"Base-excision repair of oxidative DNA damage","volume":"447","author":"David","year":"2007","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31307","article-title":"PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside","volume":"124","author":"Turk","year":"2018","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102410","article-title":"Therapeutic advances and application of PARP inhibitors in breast cancer","volume":"57","author":"Zhou","year":"2025","journal-title":"Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrm2851","article-title":"Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","volume":"11","author":"Moynahan","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: general principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett"},{"key":"B11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: Concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA -mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation\u2013associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibition in recurrent ovarian cancer","volume":"18","author":"Moore","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0343","article-title":"Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION phase IIIb study design","volume":"15","author":"Poveda","year":"2019","journal-title":"Future Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3023","article-title":"Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer: Phase III trial (L-MOCA)","volume":"28","author":"Gao","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e114","article-title":"Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study","volume":"35","author":"Aoki","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.042","article-title":"A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00680","article-title":"Discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy","volume":"58","author":"Papeo","year":"2015","journal-title":"J Med Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"gkaf086","DOI":"10.1093\/nar\/gkaf086","article-title":"XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites","volume":"53","author":"Lin","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2023.103593","article-title":"Regulatory apoptotic fragment of PARP1 complements catalytic fragment for PAR and DNA-dependent activity but inhibits DNA-induced catalytic stimulation of PARP2","volume":"133","author":"Deeksha","year":"2024","journal-title":"DNA Repair"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00301","article-title":"Structural implications for selective targeting of PARPs","volume":"3","author":"Steffen","year":"2013","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.3390\/ijms22105112","article-title":"PARP power: A structural perspective on PARP1, PARP2, and PARP3 in DNA damage repair and nucleosome remodelling","volume":"22","author":"van Beek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2024.103690","article-title":"The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication","volume":"140","author":"Zhang","year":"2024","journal-title":"DNA Repair"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9241","article-title":"Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods","volume":"8","author":"Hu","year":"2020","journal-title":"PeerJ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: Number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103125","article-title":"PARP1: Structural insights and pharmacological targets for inhibition","volume":"103","author":"Spiegel","year":"2021","journal-title":"DNA Repair"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00050","article-title":"Molecular mechanism of selective binding of NMS-P118 to PARP-1 and PARP-2: A computational perspective","volume":"7","author":"Wang","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"abq0414","DOI":"10.1126\/sciadv.abq0414","article-title":"A two-step mechanism governing PARP1-DNA retention by PARP inhibitors","volume":"8","author":"Xue","year":"2022","journal-title":"Sci Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.979873","article-title":"Current status and future promise of next-generation poly (ADP-ribose) polymerase 1-selective inhibitor AZD5305","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf7175","article-title":"Clinical PARP inhibitors allosterically induce PARP2 retention on DNA","volume":"9","author":"Langelier","year":"2023","journal-title":"Sci Adv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.27.489674","article-title":"Biomolecular condensates govern PARP inhibitor trapping and present mechanisms of resistance","author":"Gopal","year":"2022"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"422\u2013","DOI":"10.1038\/s42003-025-07840-3","article-title":"A structure-based framework for selective inhibitor design and optimization","volume":"8","author":"Zou","year":"2025","journal-title":"Commun Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"296\u2013","DOI":"10.1158\/1538-7445.AM2021-296","article-title":"Abstract 296: Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper","volume":"81","author":"Hande","year":"2021","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.13.681983","article-title":"Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity","author":"Feito","year":"2025"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12609-025-00582-5","article-title":"Targeting PARP1: A promising approach for next-generation poly (ADP-ribose) polymerase inhibitors","volume":"17","author":"Ray","year":"2025","journal-title":"Curr Breast Cancer Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2891","article-title":"Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy","volume":"34","author":"Zuo","year":"2021","journal-title":"J Mol Recognit JMR"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-356006","article-title":"From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications","volume":"118","author":"Hattangadi","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","article-title":"PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation","volume":"9","author":"Ronson","year":"2018","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice","volume":"122","author":"Farr\u00e9s","year":"2013","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg206","article-title":"Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse","volume":"22","author":"M\u00e9nissier de Murcia","year":"2003","journal-title":"EMBO J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4108","article-title":"GATA-1 regulates growth and differentiation of definitive erythroid lineage cells during in vitro ES cell differentiation","volume":"92","author":"Suwabe","year":"1998","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/iub.2192","article-title":"Regulation of GATA1 levels in erythropoiesis","volume":"72","author":"Guti\u00e9rrez","year":"2020","journal-title":"IUBMB Life"},{"key":"B58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-025-10283-1","article-title":"Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis","volume":"44","author":"Maiorano","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.06.014","article-title":"Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis","volume":"7","author":"Mohrin","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2007.11.012","article-title":"DNA repair is crucial for maintaining hematopoietic stem cell function","volume":"7","author":"Niedernhofer","year":"2008","journal-title":"DNA Repair"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1\u2013DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J Med Chem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood\u2013brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0119","article-title":"Drug\u2013gene interaction screens coupled to tumor data analyses identify the most clinically relevant cancer vulnerabilities driving sensitivity to PARP inhibition","volume":"2","author":"Jamal","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6763\u2013","DOI":"10.1158\/1538-7445.AM2026-6763","article-title":"Abstract 6763: KBD111 is a highly selective, long-acting and brain-penetrant PARP1 inhibitor","volume":"86","author":"Zhang","year":"2026","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4566\u2013","DOI":"10.1158\/1538-7445.AM2026-4566","article-title":"Abstract 4566: Discovery and characterization of CKD-9001, a novel PARP1-selective inhibitor and DNA trapper with enhanced efficacy and an improved toxicity profile in HRD cancers","volume":"86","author":"Kim","year":"2026","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-LB014","article-title":"Abstract LB014: HSK46256, a highly selective and brain penetrable PARP1 inhibitor for the treatment of HRD cancers","volume":"85","author":"Li","year":"2025","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.21037\/atm-21-1883","article-title":"Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials","volume":"9","author":"Bao","year":"2021","journal-title":"Ann Transl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231173183","article-title":"The role of PARP inhibitor combination therapy in ovarian cancer","volume":"15","author":"Hockings","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju089","article-title":"Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00857-6","article-title":"Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)","volume":"38","author":"van der Noll","year":"2020","journal-title":"Invest New Drugs"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0349-6","article-title":"Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer","volume":"120","author":"Lee","year":"2019","journal-title":"Br J Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0260","article-title":"Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer","volume":"20","author":"Tang","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2026.189552","article-title":"Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases","volume":"1881","author":"Jafari","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"10732748241298329","DOI":"10.1177\/10732748241298329","article-title":"Update on combination strategies of PARP inhibitors","volume":"31","author":"Lin","year":"2024","journal-title":"Cancer Control"},{"key":"B84","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/2767-9764.CRC-22-0423","article-title":"The PARP1 inhibitor AZD5305 impairs ovarian adenocarcinoma progression and visceral metastases in patient-derived xenografts alone and in combination with carboplatin","volume":"3","author":"Dellavedova","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.153080","article-title":"Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma","volume":"795","author":"Hassani","year":"2026","journal-title":"Biochem Biophys Res Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/toxins3070848","article-title":"Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components","volume":"3","author":"Dosio","year":"2011","journal-title":"Toxins"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2630","article-title":"Design and preclinical evaluation of a novel B7-H4\u2013directed antibody\u2013drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305","volume":"29","author":"Kinneer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac042","article-title":"Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment","volume":"4","author":"Jackson","year":"2022","journal-title":"NAR Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354427","article-title":"BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges","volume":"14","author":"Collet","year":"2024","journal-title":"Front Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121818","article-title":"BRCA1\/2 reversion mutations in patients treated with poly ADP-ribose polymerase (PARP) inhibitors or platinum agents","volume":"58","author":"Darabi","year":"2022","journal-title":"Med (Mex)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur Urol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16033","article-title":"BRCA1\/2 reversion mutations in a pan\u2010cancer cohort","volume":"115","author":"Nakamura","year":"2024","journal-title":"Cancer Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41467-024-46283-y","article-title":"GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer","volume":"15","author":"Ye","year":"2024","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426743122","article-title":"BRCA2 reversion mutation\u2013independent resistance to PARP inhibition through impaired DNA prereplication complex function","volume":"122","author":"Pappas","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1414112","article-title":"Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer","volume":"14","author":"Kulkarni","year":"2024","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40364-026-00908-0","article-title":"Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective","volume":"14","author":"Xiang","year":"2026","journal-title":"biomark Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102504","article-title":"Clinical landscape of PARP inhibitors in ovarian cancer: molecular mechanisms and clues to overcome resistance","volume":"14","author":"Kyo","year":"2022","journal-title":"Cancers"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00870-7","article-title":"Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors","volume":"29","author":"Chu","year":"2022","journal-title":"J BioMed Sci"},{"key":"B104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"biomark Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s44276-025-00122-9","article-title":"Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review","volume":"3","author":"Wang","year":"2025","journal-title":"BJC Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2409","article-title":"Preclinical In Vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146098","article-title":"SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer","volume":"6","author":"Winkler","year":"2021","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00670","article-title":"PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity","volume":"8","author":"Gupta","year":"2019","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"975\u2013","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.101804","article-title":"Comprehensive genomic profiling across diverse solid tumors: a real-world experience from India with FoundationOne\u00aeCDx testing","volume":"18","author":"Julka","year":"2026","journal-title":"Cureus"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16907","article-title":"PAR recognition by PARP1 regulates DNA\u2010dependent activities and independently stimulates catalytic activity of PARP1","volume":"290","author":"Deeksha","year":"2023","journal-title":"FEBS J"},{"key":"B114","doi-asserted-by":"publisher","first-page":"TPS279","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS279","article-title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01)","volume":"43","author":"Azad","year":"2025","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2026.2655433","article-title":"Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01","volume":"22","author":"Azad","year":"2026","journal-title":"Future Oncol Lond Engl"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of olaparib[Formula presented","volume":"79","author":"Stopsack","year":"2021","journal-title":"Eur Urol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1631\/jzus.B2400146","article-title":"Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies","volume":"27","author":"Shoaib","year":"2026","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B120","doi-asserted-by":"publisher","first-page":"106162","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00561","article-title":"The promise of selective PARP1 inhibitors in cancer therapy","volume":"16","author":"Zhou","year":"2025","journal-title":"ACS Med Chem Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:40Z","timestamp":1784867020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":121,"alternative-id":["10.3389\/fonc.2026.1894818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1894818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1894818"}}